Information for clinicians and clinical procurement.

Phant is currently supplied into the following markets, through licensed medical distributors and importers:

• United Kingdom — Cannabis-Based Products for Medicinal Use (CBPMs) under Schedule 2 of the Misuse of Drugs Regulations 2001, in line with MHRA guidance for unlicensed CBPMs. Prescribed by specialist doctors on the General Medical Council Specialist Register.
• Germany — Medical cannabis under the Betäubungsmittelgesetz (BtMG) framework, prescribed by registered physicians and dispensed through pharmacies.
• Czech Republic — Medical cannabis under the State Institute for Drug Control (SÚKL) framework.
• South Africa — Cannabis for medicinal use under the South African Health Products Regulatory Authority (SAHPRA) framework, including Section 21 access where applicable.
• Australia — Therapeutic Goods Administration (TGA) Special Access Scheme and Authorised Prescriber pathways. The clinical decision and the regulatory pathway sit with the prescribing clinician in each jurisdiction. Phant supplies finished product into licensed medical distribution and does not engage prescribing clinicians directly.

For every Phant product we can supply the following to prescribing clinicians, formulary committees, and clinical procurement teams:

• Certificate of Analysis (COA) — covering cannabinoid profile (THC, THCa, CBD, CBDa, CBG, CBN, total cannabinoids), terpene profile, microbiology, mycotoxins, heavy metals, residual solvents (where applicable), and pesticide residues. Issued per batch.
• Prescriber brief — concise clinical summary of the product, including pharmaceutical form, presentation, cannabinoid and terpene specification, recommended administration route, onset and duration characteristics where applicable, and storage conditions.
• Stability data — per format, available on request to qualified clinical contacts.
• Manufacturing standard — Health Canada GMP/GPP licence reference and supporting documentation.
• Regulatory paperwork — release documentation specific to your jurisdiction. Documentation requests are handled by our Sales and Distribution team and routed to the licensed medical distributor in your market.

• Medicinal Cannabis Flower — Indica, Sativa, and hybrid cultivars. Cannabinoid content per cultivar; terpene profile reported. Pack sizes 5g and 10g, medical-grade glass.
• Cannabis Flower Extract — solventless — Resinous Organic Extract (R.O.E.), three-stage ice-water concentrate, and the Afghan series. Granulated and pressed presentations. THC content 30–55% w/w; selected presentations carry CBD content.
• Cannabis Flower Extract — formulated — high-potency THC and 1:1 THC:CBD pressed presentations.
• Live Resin and Distillate — fresh-frozen live resin and refined distillate. 0.5ml registered medical cartridge format. 850 mg/ml THC.
• Oral Cannabis Oil — Rick Simpson Oil format, prefilled graduated syringe. 55% THC, 4.3% terpenes. Onset 60–120 minutes; duration 6–8 hours.
• Bulk Cannabis Extract — for licensed manufacturers operating in markets where local finishing is required. The full portfolio with cannabinoid, terpene, and reference lot data is at phant.ca/medical. Click any product on that page to expand its full specification.

• For COA or prescriber brief requests on a specific product: use the Request COA link in the relevant product entry on the portfolio page, or email info@phant.ca.
• For formulary submissions or volume enquiries: email our Sales and Distribution team at sales@cnpg.ca.
• For market-entry enquiries from a licensed medical distributor not currently supplied: email sales@cnpg.ca with a brief note on your jurisdiction, regulatory pathway, and approximate volume interest. We do not market directly to prescribing clinicians and we do not handle individual patient prescriptions. Prescribing decisions and patient communication remain with the prescribing clinician and the licensed distributor in your market.

Suspected adverse reactions to Phant products should be reported through the standard pharmacovigilance pathway in your jurisdiction (for example, the MHRA Yellow Card scheme in the United Kingdom). Phant collaborates with licensed medical distributors and regulators on any adverse event report received and maintains records in accordance with applicable regulations. For direct pharmacovigilance enquiries, contact info@phant.ca with the subject line Pharmacovigilance.